PL3277272T3 - Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego - Google Patents
Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowegoInfo
- Publication number
- PL3277272T3 PL3277272T3 PL16774191T PL16774191T PL3277272T3 PL 3277272 T3 PL3277272 T3 PL 3277272T3 PL 16774191 T PL16774191 T PL 16774191T PL 16774191 T PL16774191 T PL 16774191T PL 3277272 T3 PL3277272 T3 PL 3277272T3
- Authority
- PL
- Poland
- Prior art keywords
- stratification
- patients
- treatment
- methods
- receptor agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140999P | 2015-03-31 | 2015-03-31 | |
| US201562268203P | 2015-12-16 | 2015-12-16 | |
| PCT/US2016/025256 WO2016161107A1 (en) | 2015-03-31 | 2016-03-31 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-α AGONISTS |
| EP16774191.7A EP3277272B1 (en) | 2015-03-31 | 2016-03-31 | Methods of stratifying patients for treatment with retinoic acid receptor-agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3277272T3 true PL3277272T3 (pl) | 2022-01-24 |
Family
ID=57006493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16774191T PL3277272T3 (pl) | 2015-03-31 | 2016-03-31 | Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9845508B2 (pl) |
| EP (2) | EP3967305A1 (pl) |
| JP (4) | JP6952604B2 (pl) |
| KR (1) | KR20170132248A (pl) |
| CN (2) | CN116059365A (pl) |
| AU (3) | AU2016243702B2 (pl) |
| BR (3) | BR122023024814A2 (pl) |
| CA (1) | CA2981518C (pl) |
| ES (1) | ES2901792T3 (pl) |
| HU (1) | HUE057325T2 (pl) |
| IL (3) | IL309066A (pl) |
| MX (2) | MX391949B (pl) |
| PL (1) | PL3277272T3 (pl) |
| WO (1) | WO2016161107A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2906800A1 (en) | 2013-03-15 | 2014-09-18 | Avisenna Cosmetics, Llc | Topical compositions for reducing the effects of aging |
| IL309066A (en) | 2015-03-31 | 2024-02-01 | Syros Pharmaceuticals Inc | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
| IL262156B2 (en) * | 2016-04-08 | 2024-03-01 | Syros Pharmaceuticals Inc | Rara agonists for the treatment of aml and mds |
| US9868994B2 (en) | 2016-04-08 | 2018-01-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
| WO2018067946A1 (en) * | 2016-10-06 | 2018-04-12 | Syros Pharmaceuticals, Inc. | Methods of treating patients with a retinoic acid receptor-alpha agonist and an anti-cd38 antibody |
| WO2018136961A1 (en) * | 2017-01-23 | 2018-07-26 | Syros Pharmaceuticals Inc. | METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY |
| JP2019043865A (ja) * | 2017-08-31 | 2019-03-22 | ひまわり製薬株式会社 | ざ瘡様疾患を治療又は予防するための皮膚外用組成物 |
| WO2020069187A1 (en) * | 2018-09-28 | 2020-04-02 | The Children's Medical Center Corporation | Combination therapy for acute myeloid leukemia |
| BR112023002004A2 (pt) * | 2020-08-06 | 2023-04-04 | Syros Pharmaceuticals Inc | Terapias para tratamento de lma e usos de agonistas de rara, agentes hipometilativos e inibidores de bcl-2 |
| CN112390731B (zh) * | 2020-11-16 | 2022-11-25 | 成都大学 | 一种具有多靶点的维甲酸类衍生物及其制备方法与应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0170105B1 (en) | 1984-07-07 | 1990-10-17 | Koichi Prof. Dr. Shudo | Benzoic acid derivatives |
| US5089509A (en) | 1988-09-15 | 1992-02-18 | Allergan, Inc. | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity |
| JP2752630B2 (ja) | 1988-03-29 | 1998-05-18 | 大鵬薬品工業株式会社 | 新規安息香酸誘導体及びその製造方法 |
| AU1666192A (en) | 1991-03-22 | 1992-10-21 | Sloan-Kettering Institute For Cancer Research | Methods for detection and treatment of cancer |
| US5759785A (en) | 1992-05-14 | 1998-06-02 | Baylor College Of Medicine | Method of identifying hormone antagonists and agonists |
| US5455265A (en) | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
| US5824685A (en) | 1995-02-01 | 1998-10-20 | The Johns Hopkins University School Of Medicine | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
| FR2739777B1 (fr) | 1995-10-11 | 1997-11-14 | Cird Galderma | Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose |
| US5675024A (en) | 1995-11-22 | 1997-10-07 | Allergan | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
| US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
| KR100485642B1 (ko) | 1996-03-18 | 2005-09-30 | 에자이 가부시키가이샤 | 축합고리함유카르복실산유도체 |
| DE69739909D1 (de) | 1996-03-26 | 2010-07-29 | Michael S Kopreski | Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden |
| US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| WO1999020309A1 (en) | 1997-10-22 | 1999-04-29 | Eisai Co., Ltd. | Retinoic acid agonists as preventive and therapeutic agents for nephritis |
| AU1853600A (en) | 1999-01-06 | 2000-07-24 | Choong-Chin Liew | Method for the detection of gene transcripts in blood and uses thereof |
| TWI281911B (en) | 2000-04-04 | 2007-06-01 | Allergan Inc | Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents |
| WO2003025171A2 (en) * | 2001-09-17 | 2003-03-27 | Angiogene Inc. | Modulation of retinoic acid receptor gene expression and therapeutic uses thereof |
| EP2404596A1 (en) | 2006-03-23 | 2012-01-11 | TMRC Co., Ltd. | Kit for Cancer Treatment and Pharmaceutical Composition for Cancer Treatment |
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| MX2009009997A (es) | 2007-03-30 | 2009-12-08 | Tmrc Co Ltd | Preparacion de la capsula de tamibarotene. |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| US20100099084A1 (en) | 2008-10-17 | 2010-04-22 | Maher Albitar | Detection of npm1 nucleic acid in acellular body fluids |
| US20130165520A1 (en) * | 2010-02-11 | 2013-06-27 | University De Montreal | Hybrid Molecule Having Mixed Retinoic Acid Receptor Agonism and Histone Deacetylase Inhibitory Properties |
| US11116738B2 (en) * | 2012-06-07 | 2021-09-14 | Children's Hospital Los Angeles | Methods for treating neutropenia using retinoid agonists |
| WO2014066848A1 (en) | 2012-10-25 | 2014-05-01 | Whitehead Institute For Biomedical Research | Super-enhancers and methods of use thereof |
| US20140296218A1 (en) | 2012-10-25 | 2014-10-02 | Whitehead Institute For Biomedical Research | Super-enhancers and methods of use thereof |
| WO2014150300A2 (en) | 2013-03-15 | 2014-09-25 | Abbott Molecular Inc. | Method for amplification and assay of rna fusion gene variants, method of distinguishing same and related primers, probes, and kits |
| SG11201600293RA (en) | 2013-07-15 | 2016-02-26 | Univ Leland Stanford Junior | Medical uses of cd38 agonists |
| EA201691144A1 (ru) | 2013-12-06 | 2016-11-30 | Селджин Корпорейшн | Способы определения эффективности лекарственного средства для лечения диффузной крупноклеточной b-клеточной лимфомы, множественной миеломы и злокачественных новообразований миелоидного ростка |
| EP3089743B1 (en) | 2013-12-30 | 2018-07-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of an arsenic compound and at least one retinoid for treating acute myeloid leukemia |
| EP3267969A1 (en) | 2015-03-09 | 2018-01-17 | King's College London | Combination therapy with rar alpha agonists for enhancing th1 response |
| IL309066A (en) | 2015-03-31 | 2024-02-01 | Syros Pharmaceuticals Inc | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
| WO2017091762A1 (en) | 2015-11-25 | 2017-06-01 | Io Therapeutics, Inc. | Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer |
| US9868994B2 (en) | 2016-04-08 | 2018-01-16 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-α agonists |
| IL262156B2 (en) | 2016-04-08 | 2024-03-01 | Syros Pharmaceuticals Inc | Rara agonists for the treatment of aml and mds |
| WO2018067946A1 (en) | 2016-10-06 | 2018-04-12 | Syros Pharmaceuticals, Inc. | Methods of treating patients with a retinoic acid receptor-alpha agonist and an anti-cd38 antibody |
| WO2018136961A1 (en) | 2017-01-23 | 2018-07-26 | Syros Pharmaceuticals Inc. | METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY |
-
2016
- 2016-03-31 IL IL309066A patent/IL309066A/en unknown
- 2016-03-31 EP EP21188938.1A patent/EP3967305A1/en not_active Withdrawn
- 2016-03-31 EP EP16774191.7A patent/EP3277272B1/en active Active
- 2016-03-31 IL IL254697A patent/IL254697B/en unknown
- 2016-03-31 CN CN202210785569.8A patent/CN116059365A/zh active Pending
- 2016-03-31 CN CN201680028129.0A patent/CN107613969B/zh not_active Expired - Fee Related
- 2016-03-31 KR KR1020177030920A patent/KR20170132248A/ko not_active Ceased
- 2016-03-31 CA CA2981518A patent/CA2981518C/en active Active
- 2016-03-31 JP JP2017552074A patent/JP6952604B2/ja active Active
- 2016-03-31 BR BR122023024814-7A patent/BR122023024814A2/pt unknown
- 2016-03-31 BR BR112017020745-1A patent/BR112017020745A2/en not_active Application Discontinuation
- 2016-03-31 ES ES16774191T patent/ES2901792T3/es active Active
- 2016-03-31 PL PL16774191T patent/PL3277272T3/pl unknown
- 2016-03-31 IL IL294449A patent/IL294449B2/en unknown
- 2016-03-31 AU AU2016243702A patent/AU2016243702B2/en not_active Ceased
- 2016-03-31 BR BR122023024813-9A patent/BR122023024813A2/pt not_active Application Discontinuation
- 2016-03-31 WO PCT/US2016/025256 patent/WO2016161107A1/en not_active Ceased
- 2016-03-31 MX MX2017012470A patent/MX391949B/es unknown
- 2016-03-31 HU HUE16774191A patent/HUE057325T2/hu unknown
- 2016-06-02 US US15/172,045 patent/US9845508B2/en not_active Expired - Fee Related
-
2017
- 2017-09-28 MX MX2022005020A patent/MX2022005020A/es unknown
- 2017-10-31 US US15/799,519 patent/US10167518B2/en active Active
-
2018
- 2018-02-20 US US15/899,629 patent/US10697025B2/en active Active
-
2020
- 2020-05-08 US US16/870,370 patent/US11447831B2/en active Active
- 2020-08-28 JP JP2020144363A patent/JP2020203911A/ja not_active Withdrawn
-
2022
- 2022-01-06 AU AU2022200059A patent/AU2022200059B2/en not_active Ceased
- 2022-07-22 US US17/871,584 patent/US20230042181A1/en not_active Abandoned
- 2022-10-11 JP JP2022163053A patent/JP2022185101A/ja not_active Withdrawn
-
2024
- 2024-03-26 JP JP2024049322A patent/JP2024081713A/ja active Pending
- 2024-08-23 AU AU2024216311A patent/AU2024216311A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292504B1 (en) | -methods of preparing t cells for t cell therapy | |
| IL282156A (en) | Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof | |
| IL312426B2 (en) | Methods for training patients for T-cell therapy | |
| PL3277272T3 (pl) | Sposoby stratyfikacji pacjentów do leczenia agonistami receptora kwasu retinowego | |
| IL254734B1 (en) | Modified t cells and methods of making and using the same | |
| IL258358A (en) | Quantitative heart testing | |
| LT3277842T (lt) | Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais | |
| PL3355734T3 (pl) | Urządzenie do wytwarzania środka wdychalnego | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| IL252087B (en) | Methods of selecting t cell line and donor thereof for adoptive cellular therapy | |
| DK3368060T3 (da) | Glugacon-receptor-agonister | |
| EP3068783A4 (en) | Methods of treating heart failure with agonists of hypocretin receptor 2 | |
| DK3234107T3 (da) | B-celler til in vivo-levering af terapeutiske midler | |
| LT3169328T (lt) | Chinolino dariniai, skirti uždegiminių ligų gydymui | |
| ES2808978T8 (es) | Heteroarilamidas como inhibidores de la agregación de proteínas | |
| LT3007726T (lt) | Tautopatijos gydymo būdai | |
| HUE046397T2 (hu) | Artemizinin vegyületek és gefirin agonisták gyógyászati alkalmazása | |
| IL257355B (en) | Selection of patients for combination therapy | |
| DK3145530T3 (da) | Trail receptor agonists for treatment of fibrotic diseases | |
| HRP20181914T1 (hr) | Liječenje intrahepatičnih kolestatskih bolesti | |
| IL256127B (en) | Use of benzimidazole history for nocturnal acid reflux | |
| IL257764B (en) | Methods for treatment of diseases | |
| IL254825A0 (en) | Methods of treatment with taselisib | |
| IL242220A0 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| HUE062482T2 (hu) | Lactobacillus reuteri- és citráttartalmú készítmény gyógyászati felhasználásra |